Ricky Gervais, with beautiful Beagle Scarlett.

FLOE's Patron, Peter Egan, with Scarlett.

Photos © K9 Magazine

Ricky Gervais introduces Scarlett – K9 Magazine exclusive!!

K9 Magazine have published their first ever Welfare Edition and it features Ricky Gervais and FLOE’s Patron, Peter Egan meeting Scarlett, and introducing her as Beagle Ambassador for FLOE.

Enjoy K9 Magazine here .

Ricky says:

“Meeting Scarlett and sensing her painful past will stay with me forever. Like all dogs she is incredibly gentle with a heart of gold, but the horrors of two years in a toxicology laboratory are etched in her eyes and body language. This was clear, even in the relatively short time I spent with her. I’m delighted to have signed an Open Letter calling for animal experimenter Prof. Colin Blakemore to face the world’s leading medical opposition to such experiments, in a public science hearing judged by independent experts. I want people to be able to understand how these shocking experiments are now proven to also fail humans.”

Read more about how current science proves that animal experiments fail the search for human treatments and cures.


Latest peer reviewed science paper by Professor of finance Lisa Kramer and medical doctor Ray Greek, ‘Human Stakeholders and the Use of Animals in Drug Development’ 

Prof. Kramer and Dr Greek say:

“We cite hundreds of biomedical studies from journals including Nature, Science, and the Journal of the American Medical Association to show animal modeling is ineffective, misleading to scientists, unable to prevent the development of dangerous drugs, and prone to prevent the development of useful drugs. Legislation still requires animal testing prior to human testing even though the pharmaceutical sector has better options that were unavailable when animal modeling was first mandated. We propose that the U.S. Food and Drug Administration (FDA) and Congress should work together to abolish regulations and policies that require animal use. Doing so will benefit pharmaceutical industry stakeholders, including patients whose health depends on drugs and the many people who rely on the financial well‐being of pharmaceutical firms.”